This phase 2 randomized clinical trial evaluates the effect of combined selective cyclooxygenase 2 (COX-2) inhibition with standard concurrent chemoradiation therapy vs concurrent chemoradiation alone on survival among patients with unresectable stage III non–small cell lung cancer (NSCLC). The gene discussed is PTGS2; the disease is lung cancer.